Literature DB >> 23919110

Pathological aspects of so called "hilar cholangiocarcinoma".

Víctor M Castellano-Megías1, Carolina Ibarrola-de Andrés, Francisco Colina-Ruizdelgado.   

Abstract

Cholangiocarcinoma (CC) arising from the large intrahepatic bile ducts and extrahepatic hilar bile ducts share clinicopathological features and have been called hilar and perihilar CC as a group. However, "hilar and perihilar CC" are also used to refer exclusively to the intrahepatic hilar type CC or, more commonly, the extrahepatic hilar CC. Grossly, a major distinction can be made between papillary and non-papillary tumors. Histologically, most hilar CCs are well to moderately differentiated conventional type (biliary) carcinomas. Immunohistochemically, CK7, CK20, CEA and MUC1 are normally expressed, being MUC2 positive in less than 50% of cases. Two main premalignant lesions are known: biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm of the biliary tract (IPNB). IPNB includes the lesions previously named biliary papillomatosis and papillary carcinoma. A series of 29 resected hilar CC from our archives is reviewed. Most (82.8%) were conventional type adenocarcinomas, mostly well to moderately differentiated, although with a broad morphological spectrum; three cases exhibited a poorly differentiated cell component resembling signet ring cells. IPNB was observed in 5 (17.2%), four of them with an associated invasive carcinoma. A clear cell type carcinoma, an adenosquamous carcinoma and two gastric foveolar type carcinomas were observed.

Entities:  

Keywords:  Bile duct carcinoma; Cholangiocarcinoma; Extrahepatic bile duct carcinoma; Hepatic hilum; Hilar cholangiocarcinoma; Klatskin tumor; Perihilar cholangiocarcinoma

Year:  2013        PMID: 23919110      PMCID: PMC3731529          DOI: 10.4251/wjgo.v5.i7.159

Source DB:  PubMed          Journal:  World J Gastrointest Oncol


  74 in total

1.  Noninvasive and minimally invasive papillary carcinomas of the extrahepatic bile ducts.

Authors:  J Albores-Saavedra; L Murakata; J E Krueger; D E Henson
Journal:  Cancer       Date:  2000-08-01       Impact factor: 6.860

2.  Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms.

Authors:  Hiroaki Shibahara; Shugo Tamada; Masamichi Goto; Koji Oda; Masato Nagino; Tetsuro Nagasaka; Surinder K Batra; Michael A Hollingsworth; Kohzoh Imai; Yuji Nimura; Suguru Yonezawa
Journal:  Am J Surg Pathol       Date:  2004-03       Impact factor: 6.394

3.  Clinicopathologic studies on perineural invasion of bile duct carcinoma.

Authors:  M R Bhuiya; Y Nimura; J Kamiya; S Kondo; S Fukata; N Hayakawa; S Shionoya
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

4.  Intraductal papillary neoplasm of the bile duct: a biliary equivalent to intraductal papillary mucinous neoplasm of the pancreas?

Authors:  Flavio G Rocha; Hwajeong Lee; Nora Katabi; Ronald P DeMatteo; Yuman Fong; Michael I D'Angelica; Peter J Allen; David S Klimstra; William R Jarnagin
Journal:  Hepatology       Date:  2012-08-27       Impact factor: 17.425

5.  Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.

Authors:  A Rullier; B Le Bail; R Fawaz; J F Blanc; J Saric; P Bioulac-Sage
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

6.  The concept of perihilar cholangiocarcinoma is valid.

Authors:  T Ebata; J Kamiya; H Nishio; T Nagasaka; Y Nimura; M Nagino
Journal:  Br J Surg       Date:  2009-08       Impact factor: 6.939

Review 7.  Pathologic staging of pancreatic, ampullary, biliary, and gallbladder cancers: pitfalls and practical limitations of the current AJCC/UICC TNM staging system and opportunities for improvement.

Authors:  N Volkan Adsay; Pelin Bagci; Takuma Tajiri; Irma Oliva; Nobuyuki Ohike; Serdar Balci; Raul S Gonzalez; Olca Basturk; Kee-Taek Jang; Juan Carlos Roa
Journal:  Semin Diagn Pathol       Date:  2012-08       Impact factor: 3.464

8.  Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors.

Authors:  A Nakeeb; H A Pitt; T A Sohn; J Coleman; R A Abrams; S Piantadosi; R H Hruban; K D Lillemoe; C J Yeo; J L Cameron
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

9.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

10.  Squamous cell carcinoma of the hilar bile duct.

Authors:  Ippei Yamana; Shunji Kawamoto; Shuji Nagao; Takahisa Yoshida; Yuichi Yamashita
Journal:  Case Rep Gastroenterol       Date:  2011-08-22
View more
  8 in total

Review 1.  Imaging and interventions in hilar cholangiocarcinoma: A review.

Authors:  Kumble Seetharama Madhusudhan; Shivanand Gamanagatti; Arun Kumar Gupta
Journal:  World J Radiol       Date:  2015-02-28

2.  Rapidly Progressing Primary Extrahepatic Bile Duct Signet-Ring Cell Carcinoma in a Caucasian Woman.

Authors:  Jessemae L Welsh; Omar Jaber; Marina Ivanovic; Frederick C Johlin; Rami G El Abiad; Gerald H Clamon; Mark C Smith; Carlos H F Chan
Journal:  J Gastrointest Cancer       Date:  2018-03

3.  Living donor liver transplantation for hepatocellular carcinoma at the University of Tokyo Hospital.

Authors:  Junichi Togashi; Nobuhisa Akamastu; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

4.  Hilar cholangiocarcinoma.

Authors:  José M Ramia
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

Review 5.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

6.  Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma.

Authors:  Yu Wang; Wei Cui; Wenzhe Fan; Yingqiang Zhang; Wang Yao; Kunbo Huang; Jiaping Li
Journal:  Oncotarget       Date:  2016-08-16

7.  Percutaneous transhepatic biliary drainage may be the preferred preoperative drainage method in hilar cholangiocarcinoma.

Authors:  Yongjiang Ba; Ping Yue; Joseph W Leung; Haiping Wang; Yanyan Lin; Bing Bai; Xiaoliang Zhu; Lei Zhang; Kexiang Zhu; Wenhui Wang; Wenbo Meng; Wence Zhou; Ying Liu; Xun Li
Journal:  Endosc Int Open       Date:  2020-01-22

8.  Actual 10-Year Survival after Resection of Perihilar Cholangiocarcinoma: What Factors Preclude a Chance for Cure?

Authors:  Anne-Marleen van Keulen; Pim B Olthof; Matteo Cescon; Alfredo Guglielmi; William R Jarnagin; Silvio Nadalin; Johann Pratschke; Francesca Ratti; Roberto I Troisi; Bas Groot Koerkamp; Stefan Buettner; Joris I Erdmann
Journal:  Cancers (Basel)       Date:  2021-12-13       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.